Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications.

@article{Kovarik2001PopulationPO,
  title={Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications.},
  author={John M. Kovarik and Ching Hsiang Hsu and Louis McMahon and St{\'e}phane Berthier and Christiane Rordorf},
  journal={Clinical pharmacology and therapeutics},
  year={2001},
  volume={70 3},
  pages={247-54}
}
BACKGROUND Everolimus is a macrolide immunosuppressant intended for acute rejection prophylaxis after kidney transplantation. METHODS A total of 5260 blood samples were collected in the context of two randomized, double-blind, multicenter efficacy trials in 673 patients over a 6-month period after kidney transplantation. The data were evaluated in a nonlinear mixed-effects model. The influence of demographic characteristics (age, weight, sex, and ethnicity) and of comedications on everolimus… CONTINUE READING